Karyopharm Therapeutics Inc. (KPTI) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have earned an average rating of “Buy” from the fourteen ratings firms that are currently covering the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $15.41.
A number of research analysts have issued reports on KPTI shares. Jefferies Group upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and increased their target price for the stock from $9.00 to $12.00 in a research report on Tuesday, August 30th. HC Wainwright increased their target price on shares of Karyopharm Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, September 8th. Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. S&P Equity Research decreased their target price on shares of Karyopharm Therapeutics from $9.06 to $7.55 in a research report on Tuesday, August 30th. Finally, Leerink Swann restated an “outperform” rating and set a $18.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, October 7th.
In other news, insider Ran Frenkel sold 3,309 shares of the firm’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $10.06, for a total transaction of $33,288.54. Following the completion of the transaction, the insider now owns 14,691 shares of the company’s stock, valued at $147,791.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 14.79% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its position in Karyopharm Therapeutics by 631.9% in the first quarter. Wellington Management Group LLP now owns 1,269,485 shares of the company’s stock valued at $11,323,000 after buying an additional 1,096,029 shares during the last quarter. Baker BROS. Advisors LP purchased a new position in shares of Karyopharm Therapeutics during the third quarter worth $2,111,000. New Leaf Venture Partners L.L.C. increased its position in shares of Karyopharm Therapeutics by 1,723.5% in the second quarter. New Leaf Venture Partners L.L.C. now owns 222,947 shares of the company’s stock worth $1,496,000 after buying an additional 210,721 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Karyopharm Therapeutics by 18.5% in the second quarter. Vanguard Group Inc. now owns 816,444 shares of the company’s stock worth $5,478,000 after buying an additional 127,714 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. increased its position in shares of Karyopharm Therapeutics by 68.8% in the third quarter. Candriam Luxembourg S.C.A. now owns 270,000 shares of the company’s stock worth $2,627,000 after buying an additional 110,000 shares in the last quarter. 49.20% of the stock is owned by hedge funds and other institutional investors.
Karyopharm Therapeutics (NASDAQ:KPTI) opened at 9.87 on Wednesday. The company’s market cap is $407.07 million. Karyopharm Therapeutics has a 52-week low of $4.83 and a 52-week high of $19.41. The company has a 50-day moving average of $8.75 and a 200 day moving average of $8.29.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Monday, November 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.12. Equities research analysts predict that Karyopharm Therapeutics will post ($3.00) EPS for the current year.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.